Magnetic resonance imaging captures the biology of ductal carcinoma in situ

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4603-4610

  Esserman, Laura J ^a   Kumar, Anjali S ^a   Herrera, Alex F ^a   Leung, Jessica ^a   Au, Alfred ^a   Chen, Yunn Yi ^a   Moore, Dan H ^a   Chen, Daniel F ^a   Hellawell, Jennifer ^a   Wolverton, Dulcy ^a   Hwang, E Shelley ^a   Hylton, Nola M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; CD68 ANTIGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL FEATURE; COMEDO; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR BIOPSY; BIOSYNTHESIS; BREAST TUMOR; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; RADIOGRAPHY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 33750587397     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.5518     Document Type: Article

References (30)

1. Morrow M, Strom EA, Bassett LW, et al: Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52:256-276, 2002
2. Schnitt SJ, Connolly JL: Classification of ductal carcinoma in situ: Striving for clinical relevance in the era of breast conserving therapy. Hum Pathol 28:877-880, 1997
3. Allred DC, O'Connell P, Fuqua SA, et al: Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 32:13-18, 1994
4. Fisher ER, Dignam J, Tan-Chiu E, et al: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma. Cancer 86:429-438, 1999
5. Hetelekidis S, Collins L, Silver B, et al: Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer 85:427-431, 1999
6. Jensen RA, Page DL: Ductal carcinoma in situ of the breast: Impact of pathology on therapeutic decisions. Am J Surg Pathol 27:828-831, 2003
7. Silverstein MJ, Lagios MD, Groshen S, et al: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455-1461, 1999
8. Vicini FA, Kestin LL, Goldstein NS, et al: Relationship between excision volume, margin status, and tumor size with the development of local recurrence in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Surg Oncol 76:245-254, 2001
9. Sanders ME, Schuyler PA, Dupont WD, et al: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481-2484, 2005
10. Frykberg ER, Bland KI: Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74:350-361, 1994
11. Sakorafas GH, Tsiotou AG: Ductal carcinoma in situ (DCIS) of the breast: Evolving perspectives. Cancer Treat Rev 26:103-125, 2000
12. Ernster VL: Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med 340:1838, 1999
13. Ernster VL, Barclay J, Kerlikowske K, et al: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913-918, 1996
14. Kumar AS, Bhatia V, Henderson IC: Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ - A US perspective. Breast Cancer Res 7:271-275, 2005
15. Gabrielson E, Argani P: Heterogeneity in the pathology and molecular biology of breast cancer. Current Genomics 3:477-488, 2002
16. Hwang ES, Esserman L: Neoadjuvant hormonal therapy for ductal carcinoma in situ: Trial design and preliminary results. Ann Surg Oncol 11:37S-43S, 2004 (suppl 1)
17. Kumar AS, Esserman LJ: Statins: Health-promoting agents show promise for breast cancer prevention. Clin Breast Cancer 6:455-459, 2005
18. Zuiani C, Francescutti GE, Londero V, et al: Ductal carcinoma in situ: Is there a role for MRI? J Exp Clin Cancer Res 21:89-95, 2002
19. Hylton N: Magnetic resonance imaging of the breast: Opportunities to improve breast cancer management. J Clin Oncol 23:1678-1684, 2005
20. Esserman L, Hylton N, Yassa L, et al: Utility of magnetic resonance imaging in the management of breast cancer: Evidence for improved preoperative staging. J Clin Oncol 17:110-119, 1999
21. Kumar AS, Chen DF, Au A, et al: Biologic significance of false positive MRI enhancement in the setting of DCIS. Am J Surg (in press)
22. Hiramatsu H, Ikeda T, Mukai M, et al: MRI of ductal carcinoma in situ of the breast: Patterns of findings and evaluation of disease extent. Nippon Igaku Hoshasen Gakkai Zasshi 60:205-209, 2000
23. Ikeda DM, Hylton NM, Kinkel K, et al: Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging 13:889-895, 2001
24. ACR BI-RADS: Breast Imaging and Reporting Data System-Magnetic Resonance Imaging. Reston, VA, American College of Radiology, 2004, pp 1-114
25. Hwang ES, Kinkel K, Esserman LJ, et al: Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: Value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 10:381-388, 2003
26. Kneeshaw PJ, Lowry M, Manton D, et al: Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging. Breast 15:29-38, 2006
27. Esserman L, Hylton N, George T, et al: Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 5:13-21, 1999
28. Mylonas I, Makovitzky J, Jeschke U, et al: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25:1719-1723, 2005
29. Kerlikowske K, Molinaro A, Cha I, et al: Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95:1692-1702, 2003
30. Esserman L, Sepucha K, Ozanne E, et al: Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 11:28S-36S, 2004 (suppl 1)